Expression of IL1β and CCL2 is increased in AD [61,62], and both have been discussed as pathogenicity factors and biomarkers for, e.g., progression from mild cognitive impairment (MCI) to AD [63,64,65]. The gene discussed is CCL2; the disease is Cognitive impairment.